Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(13):961; doi:10.1093/jnci/93.13.961
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 13, 961, July 4, 2001
© 2001 Oxford University Press

IN THIS ISSUE

Tamoxifen Therapy and Risk of Contralateral Breast Cancer

Women who have been diagnosed with breast cancer have a two- to sixfold greater risk of developing contralateral breast cancer than women in the general population have of developing a first breast cancer. Tamoxifen therapy reduces a woman’s risk of developing contralateral breast cancer, but it is not known whether tamoxifen use affects the development of both estrogen receptor (ER)-positive and ER-negative contralateral tumors. Li et al. (p. 1008) used data from a population-based tumor registry to assess this relationship. The authors found that women treated with tamoxifen for a . . . [Full Text of this Article]

Retroviral Endostatin In Vivo

Consensus Statement: Adjuvant Therapy for Breast Cancer

4-HPR and Esophageal Tumorigenesis in Rats

Recombinant Canarypox Viruses in a Prostate Cancer Model

Nasopharyngeal Radium Irradiation and Cancer Mortality


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?